Business
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
SAN DIEGO, January 12, 2026--Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
About this update from Dexcom, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/31c4cb2e212cffbe8abb7748284626df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xY.dVXjpzz2A3A03kXgR1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/31c4cb2e212cffbe8abb7748284626df","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xx0e3qRW6IWB62RogkYDrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/31c4cb2e212cffbe8abb7748284626df","width":1024,"height":512}},"lazy":false},{"type":"text","content":"SAN DIEGO, January 12, 2026--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the fourth quarter of 2024. U.S. revenue is expected to be approximately $892 million, representing growth of 11% over the fourth quarter of 2024. International revenue is expected to be approximately $368 million, an increase of 18% over the fourth quarter of 2024.","length":509,"tagName":"p"},{"type":"text","content":"For fiscal 2025, total preliminary, unaudited revenue is approximately $4.662 billion, an increase of 16% over 2024. In conjunction with the preliminary fourth quarter results, the company is also reiterating 2025 non-GAAP gross profit margin guidance of approximately 61% and non-GAAP operating margin guidance of 20-21%.","length":322,"tagName":"p"},{"type":"text","content":""We are pleased to finish 2025 on a strong note with revenue exceeding the high end of our guidance and the initial launch of our latest sensor technology with the G7 15 Day system," said Jake Leach, Dexcom’s president and CEO. "With clinical momentum building across the CGM category, we look forward to extending our growth runway through continued innovation and evidence generation in 2026."","length":415,"tagName":"p"},{"type":"text","content":"2026 Outlook","length":12,"tagName":"p"},{"type":"text","content":"For 2026, Dexcom currently anticipates total revenue of $5.16 - $5.25 billion, representing expected growth of approximately 11-13% over 2025. Th...